Skip to main content
Find more clinical trials

Citalopram for Agitation in Alzheimer's Disease (CitAD)

Start: July 2009
End: September 2013
Enrollment: 200

What Is This Study About?

The purpose of this study is to evaluate the safety and efficacy of the drug citalopram for treating agitation in Alzheimer's dementia.

Do I Qualify To Participate in This Study?

Minimum Age: N/A

Maximum Age: N/A

Must have:

++Probable Alzheimer's disease (NINCDS-ADRDA criteria), with MMSE score of 5-28++Clinically significant agitation for which a medication is needed, individual has score ≥ 4 on the Neuropsychiatric Inventory (NPI) agitation domain, and more than two agitated behaviors per week++Availability of primary caregiver, who spends several hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study++Sufficient fluency, of the patient and caregiver, in written and spoken English or Spanish++Stable treatment for Alzheimer's disease with cholinesterase inhibitors and/or memantine

Must NOT have:

++Major depression++Brain disease that might otherwise explain the presence of dementia, such as extensive brain vascular disease, Parkinson's disease, dementia with Lewy bodies, traumatic brain injury, or multiple sclerosis++Psychosis (delusions or hallucinations) requiring antipsychotic treatment++Need for psychiatric hospitalization or acutely suicidal++Current participation in a clinical trial or any study that may add a significant burden or affect study outcomes++Any condition that makes it medically inappropriate or risky for the patient to enroll in the trial++Prohibited medications: Citalopram; failure of past treatment with citalopram for agitation after adequate trial at a minimally accepted dose (greater than or equal to 20 mg/day); any medication that would prohibit the safe concurrent use of citalopram, such as MAO inhibitors; current treatment with antipsychotics, anticonvulsants, other antidepressants (other than trazodone, less than or equal to 50 mg/day at bedtime), benzodiazepines (other than lorazepam), or psychostimulants

 
Study Contact
Anne Roche

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

California
University of Southern California Keck School of Medicine Memory and Aging Center
Los Angeles, CA 90089
VA Palo Alto Health Care System
Palo Alto, CA 94304
Maryland
Johns Hopkins University
Baltimore, MD 21224
New York
Columbia University
New York, NY 10032
Monroe Community Hospital
Rochester, NY 14559
Pennsylvania
University of Pennsylvania, Section of Geriatric Psychiatry, Ralston House
Philadelphia, PA 19104
South Carolina
Medical University of South Carolina Alzheimer's Research and Clinical Programs
Charleston, SC 29406

Who Sponsors This Study?

Lead: Johns Hopkins University

Collaborator Sponsor

  • National Institute on Aging (NIA)
  • National Institute of Mental Health (NIMH)

Source: ClinicalTrials.gov ID: NCT00898807